Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study
Biologics used for psoriasis, with the exception of brodalumab, exhibit a lower frequency of pregnancy-related adverse outcomes compared to TNF-α inhibitors and certolizumab pegol, suggesting their potential to be safe options during pregnancy. However, further studies are necessary to evaluate the safety of these biologics during pregnancy, accounting for confounding factors.
Authors
- Wonwoo Jang (ORCID: https://orcid.org/0009-0008-1070-3232)
- Jaeyu Park (ORCID: https://orcid.org/0009-0005-2009-386X)
- Hayeon Lee (ORCID: https://orcid.org/0009-0000-2403-6241)
- Kyeongmin Lee (ORCID: https://orcid.org/0009-0004-0379-2151)
- Dong Keon Yon (ORCID: https://orcid.org/0000-0003-1628-9948)
- Lee Smith (ORCID: https://orcid.org/0000-0002-5340-9833)
- Xuerong Wen (ORCID: https://orcid.org/0000-0002-4803-7895)
- Sooji Lee (ORCID: https://orcid.org/0009-0002-1413-378X)
- Jiyeon Oh (ORCID: https://orcid.org/0009-0005-3291-4370)
- Yi Deun Jeong
- Hyesu Jo
- Hanseul Cho (ORCID: https://orcid.org/0009-0005-7463-4094)
Institutions
- University of Rhode Island (US)
- Kyung Hee University (KR)
- Kyung Hee University Medical Center (KR)
- Anglia Ruskin University (GB)
Publication Details
- Journal
- International Archives of Allergy and Immunology
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1159/000542217
- Citations
- 16
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 8.69
Funders
- World Health Organization
- National Research Foundation
- Kyung Hee University
- National Research Foundation of Korea
- Iran Telecommunication Research Center
- Ministry of Science and ICT, South Korea
- Institute for Information and Communications Technology Promotion